We would love to hear your thoughts about our site and services, please take our survey here.
Posting in case it’s of interest to anyone, FDA just approved a therapy for mantle cell lymphoma (MCL) using CAR-T cells
https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-adult-patients-relapsed-or-refractory-mcl
@dufry in at ~108p out at ~212p (I had multiple trades) in the morning, so again thanks for the mention on here! ;-) and I bought back in on the afternoon drop at 155p and after research I've decided to hold tight there now too - let's hope it pays off!
@jhfh I appreciate the detailed response thank you. I hadn't appreciated it was more like a regurgitation of an old study which is potentially very niche, and your suggestion of their reasons is possible. Glad you don't think it's a threat anyway, but if @pingu etc. have any thoughts too to confirm that would be great?
@joey I guess the difference now being you've got new investors/traders that bought from 155p upwards and probably are happy to cash in a 20% gain if it starts dropping... let's hope they hold tight but who knows
@jhfh thanks for responding but if that's the case it seems to happen an awful lot on here and never on any other shares I'm in...
The competitor news I was referring to previously was this one https://www.lse.co.uk/rns/SAR/research-update-pk3freb7q3q94uc.html @jhfh you're probably the most knowledgeable on here tbh, do you have any thoughts?
(let's see if this gets removed for no reason whatsoever)
What the hell... why has my competitors post been removed? Who reported it? I'm not in that other share, I've no interest in being in it, I posted it as a discussion topic because they are developing a treatment against lupus - is that not worthy of discussion..?
Geez I've said it before but this board is ridiculous for trying to censor anything that challenges HEMO. I'm a shareholder and was just interested in people's thoughts
@matt ok thanks, not been through all the posts. Just surprised the doctor listed these wrong in his video because when he said about them being in the SNG001 group it was definitely a big positive, shame it's the other way around. Like you say though the overall co-morbidities are essentially even across both groups.
@notbot I thought Dr John Campbell said the higher number of diabetes and cardiovascular disease patients were in the SNG001 group... hmm... I hadn't looked through the SNG presentation since watching his YouTube
@adam can you explain why you think the deal announcement is late? In the 18 June presentation they gave a target of 3-6 weeks for completion, basically end of July would be the deadline. So based on that we’ve got another week before it can be classed as late?
@safy do you mean why is this board fixated with NHS? I’m only dipping in and out at the moment so don’t know the general consensus on here. But ever since DB told us the target markets are India, US and Africa I’ve not had a focus on UK - but keep tabs on the DHSC website. Far bigger fish in the world than the NHS and in places where GDR’s temp stable test can make a huge difference. Patience is key here, as most of us have learnt in the last few months, but the reward imo will be well worth it
@frank thanks for sharing that, great For SNG to have such a long segment with Fox News radio and Marsden did well in explaining the intricacies of SNG001 and it’s benefits, as well as the steps for the next push forward to get this out to the people that desperately need it. Exciting times for sure!
@safy you do know where the NHS link has come from, it's been mentioned enough on here whilst you've been around, it's from the comments made on the GDR submission on the DHSC website https://testingmethods.crowdicity.com/post/3237330 That being said, I still don't believe the UK market is GDR's focus...